Brain tumor immunotherapy: Seeing the brain in the body

Drug Discovery Today

Volumn 18, Issue 7-8, 2013, Pages 399-406

  Lampson, Lois A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RESISTANCE; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; PASSIVE IMMUNIZATION; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; HUMANS; IMMUNOTHERAPY;

EID: 84875705324     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.11.007     Document Type: Review

References (60)

1. O.M. Grauer Immunotherapy of diffuse gliomas: biological background, current status and future developments Brain Pathol. 19 2009 674 693
2. S. Van Gool Dendritic cell therapy of high-grade gliomas Brain Pathol. 19 2009 694 712
3. C.J. Wheeler Dendritic cell vaccines to combat glioblastoma Exp. Rev. Neurother. 10 2010 483 486
4. L.A. Lampson Targeted therapy for neuro-oncology: reviewing the menu Drug Discov. Today 14 2009 185 191
5. P. Gupta Development of an EGFRvIII specific recombinant antibody BMC Biotechnol. 10 2010 72
6. N. Ahmed HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors Clin. Cancer Res. 16 2010 474 485
7. J.J. Hong Successful treatment of melanoma brain metastases with adoptive cell therapy Clin. Cancer Res. 16 2010 4892 4898
8. L.A. Lampson Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier MAbs 3 2011 153 160
9. S. Nagpal Treatment and prevention of secondary CNS lymphoma Semin. Neurol. 30 2010 263 272
10. V. Voelter An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain Cancer Immun. 8 2008 6
11. V. Corbiere Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases Cancer Res. 71 2011 1253 1262
12. G. Cartron Interindividual variability of response to rituximab: from biological origins to individualized therapies Clin. Cancer Res. 17 2011 19 30
13. E. Vauleon Overview of cellular immunotherapy for patients with glioblastoma Clin. Dev. Immunol. 2010 10.1155/2010/689171
14. L.A. Lampson Brain tumor models to predict clinical outcome: like the phoenix? R.M. Murillo, A. Martinez, Animal Models of Brain Tumors 2013 Humana
15. P.Y. Dietrich T-cell immunotherapy for malignant glioma: toward a combined approach Curr. Opin. Oncol. 22 2010 604 610
16. M.Z. Ladjemi Anti-HER2 vaccines: new prospects for breast cancer therapy Cancer Immunol. Immunother. 59 2010 1295 1312
17. O. Thaunat Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis Blood 116 2010 515 521
18. L.A. Lampson Basic principles of CNS immunology H.R. Winn, Youman's Neurological Surgery 2003 Saunders 673 688
19. C.J. Harling-Berg Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation J. Neuroimmunol. 101 1999 111 127 (Pubitemid 29516453)
20. E.K. Rainey-Barger The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system Brain Behav. Immun. 25 2011 922931
21. J.V. Kim Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis Nature 457 2009 191 195
22. F. Pfeiffer Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis Acta Neuropathol. 122 2011 601 614
23. J. Van den Bossche Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs Blood 119 2012 1623 1633
24. 1 T cells for immunotherapy Cancer Immunol. Immunother. 60 2011 173 186
25. 1 T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40T antigen-induced brain tumors J. Immunol. 181 2008 4406 4417
26. I. Mellman Cancer immunotherapy comes of age Nature 480 2011 480 489
27. G. Orive Biomaterial-based technologies for brain anti-cancer therapeutics and imaging Biochim. Biophys. Acta 1806 2010 96 107
28. J.D. Ebben Tumour vaccine approaches for CNS malignancies: progress to date Drugs 69 2009 241 249
29. R. Yamanaka Dendritic-cell- and peptide-based vaccination strategies for glioma Neurosurg. Rev. 32 2009 265 273 discussion 273
30. B.S. Sheridan, and L. Lefrancois Regional and mucosal memory T cells Nat. Immunol. 12 2011 485 491
31. F.A. Schildberg Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells Eur. J. Immunol. 38 2008 957 967
32. G. Kraal The importance of regional lymph nodes for mucosal tolerance Immunol. Rev. 213 2006 119 130 (Pubitemid 44401497)
33. I.M. Belyakov, and J.D. Ahlers What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183 2009 6883 6892
34. T. Calzascia Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes Glia 56 2008 1625 1636
35. D.L. Thomas Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors Cancer Immunol. Immunother. 57 2008 1323 1333
36. L.P. McCluskey, and L.A. Lampson Local neurochemicals and site-specific immune regulation in the CNS J. Neuropathol. Exp. Neurol. 59 2000 177 187 (Pubitemid 30143876)
37. L. Zhang Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice Glia 57 2009 1458 1467
38. K. Sakakura Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides Clin. Immunol. 125 2007 43 51 (Pubitemid 47374535)
39. G. Bindea Natural immunity to cancer in humans Curr. Opin. Immunol. 22 2010 215 222
40. S.I. Grivennikov Immunity, inflammation, and cancer Cell 140 2010 883 899
41. M.M. Fort, and P.K. Narayanan Manipulation of regulatory T-cell function by immunomodulators: a boon or a curse? Toxicol. Sci. 117 2010 253 262
42. T.T. Hansel The safety and side effects of monoclonal antibodies Nat. Rev. Drug Discov. 9 2010 325 338
43. M.L. Disis Immunologic biomarkers as correlates of clinical response to cancer immunotherapy Cancer Immunol. Immunother. 60 2011 433 442
44. A. Facciabene Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells Nature 475 2011 226 230
45. J.H. Sampson Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J. Clin. Oncol. 28 2010 4722 4729
46. L.A. Lampson Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis Ann. Neurol. 28 1990 365 372 (Pubitemid 20292623)
47. N. Corazza Immune cell-mediated liver injury Semin. Immunopathol. 31 2009 267 277
48. N. Srinivasan Telling apart friend from foe: discriminating between commensals and pathogens at mucosal sites Innate Immun. 16 2010 391 404
49. F. van Wijk, and H. Cheroutre Intestinal T cells: facing the mucosal immune dilemma with synergy and diversity Semin. Immunol. 21 2009 130 138
50. B.W. Bridle Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen J. Immunol. 184 2010 4269 4275
51. L.A. Lampson Immune regulation in the brain: lessons from autoimmunity, implications for brain tumor therapy F. Ali-Osman, Brain Tumors 2005 Humana 175 205
52. O.M. Grauer TLR ligands in the local treatment of established intracerebral murine gliomas J. Immunol. 181 2008 6720 6729
53. K. Aoshima Possible origin of CSF antibodies induced by intrathecal immunization and prophylactic effects against intracerebral rabies virus infection J. Vet. Med. Sci. 73 2011 1303 1308
54. L.A. Lampson, and W.F. Hickey Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from 'histologically normal' to that showing different levels of glial tumor involvement J. Immunol. 136 1986 4054 4062 (Pubitemid 16123050)
55. 1 T cells that are effective in adoptive therapy for large and established tumors Blood 117 2011 118 127
56. P.D. Greenberg Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells Adv. Immunol. 49 1991 281 355
57. T. Dutta Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains J. Neuro-oncology 64 2003 31 44 (Pubitemid 36992458)
58. M. Campone Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation Crit. Rev. Oncol./Hematol. 78 2011 195 205
59. J. Zhang Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 2010 501 506
60. L.A. Lampson Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ Cancer Res. 53 1993 176 182 (Pubitemid 23019395)